100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Zusammenfassung Vorlesung G2 Psychopharmakologie $5.02
Add to cart

Summary

Zusammenfassung Vorlesung G2 Psychopharmakologie

 10 views  2 purchases
  • Course
  • Institution

Alle Folien und Kommentare zur Vorlesung

Preview 4 out of 124  pages

  • July 11, 2022
  • 124
  • 2021/2022
  • Summary
avatar-seller
Einführung ................................................................................................................................... 8
Grundlegende Begriffe ........................................................................................................................ 8
Resorption, Distribution und Elimination............................................................................................ 9
Pharmakokinetik .......................................................................................................................... 9
Applikation von Pharmaka .................................................................................................................. 9
Metabolismus und Elimination ......................................................................................................... 13
Blut-Hirn-Schranke ............................................................................................................................ 14
Depletionsexperimente ................................................................................................................. 14
Zusammenfassung: pharmakokinetische Kenngrößen ..................................................................... 15
Klassifikation der Neuropsychopharmaka......................................................................................... 15
Informationsquellen .......................................................................................................................... 16
Pharmakodynamik ..................................................................................................................... 17
Dosis-Wirkungsbeziehung ................................................................................................................. 17
Pharmakodynamik: Kennwerte ......................................................................................................... 18
Pharmakokinetische Interaktionen ................................................................................................... 19
Ebene der Resorption .................................................................................................................... 19
Ebene der Verteilung ..................................................................................................................... 19
Ebene des Metabolismus .............................................................................................................. 20
Ebene der Ausscheidung ............................................................................................................... 21
Pharmakodynamische Interaktionen ................................................................................................ 22
Transmittersysteme ................................................................................................................... 23
Wirkungsmechanismen der Transmitter........................................................................................... 25
Interaktionen an Rezeptoren ........................................................................................................ 27
Rezeptorbindung und -wirkung ..................................................................................................... 27
Pharmakawirkungen auf Transmittersysteme .................................................................................. 28
Angriffspunkte der Psychopharmaka ............................................................................................ 28
Neurotransmitter .............................................................................................................................. 29
Glutamat ........................................................................................................................................ 29
GABA.............................................................................................................................................. 31
Acetylcholin ................................................................................................................................... 32
Cholinerges System ........................................................................................................................... 32
Rezeptorbeeinflussung im cholinergen System ............................................................................ 34
Neuromodulatoren............................................................................................................................ 35

1

, Monoaminerge Systeme ................................................................................................................... 35
Noradrenalin/ Norepinephrine ..................................................................................................... 36
Serotonin (5-HT) ............................................................................................................................ 36
Monoamine (Dopamin) .............................................................................................................. 38
dopaminerge System(e) .................................................................................................................... 38
Dopaminsynthese und -metabolismus.............................................................................................. 38
Elimination..................................................................................................................................... 39
Dopaminrezeptoren .......................................................................................................................... 39
Dopaminerge Synapse im Kortex .................................................................................................. 41
Aktivitätsmodi dopaminerger Zellen ............................................................................................. 42
Dopaminkonzentration im PFC vs. Striatum ..................................................................................... 42
Dopamin im präfrontalen Kortex (PFC) ......................................................................................... 42
Zwei-Zustandsmodell der DA-Wirkung im PFC ............................................................................. 43
Dopamin und Lernen ......................................................................................................................... 44
phasisches DA & Verstärkungslernen............................................................................................ 44
Vorhersagefehler ........................................................................................................................... 44
Temporal difference learning ........................................................................................................ 45
DA und Belohungsvorhersage ....................................................................................................... 46
VTA / SNc in humans ..................................................................................................................... 46
error-related negativity (ERN, Ne)................................................................................................. 46
Dopamin und Handlungsüberwachung ............................................................................................. 47
Dopamin und Entscheidung .............................................................................................................. 48
DA in den Basalganglien ................................................................................................................ 48
Probabilistische Wahlaufgabe ....................................................................................................... 49
DRD2 / ANKK1 TAQ IA Polymorphism ............................................................................................... 50
DRD2 und probabilistische Wahlaufgabe ...................................................................................... 50
Zusammenfassung Dopamin ............................................................................................................. 51
Antipsychotika ........................................................................................................................... 52
Geschichte ......................................................................................................................................... 52
Schizophrenie .................................................................................................................................... 53
Entwicklung schizophrener Psychosen.............................................................................................. 54
Risikofaktoren................................................................................................................................ 54
Vulnerabilitäts-Stress-Modell ........................................................................................................ 54
Genetische Befunde ...................................................................................................................... 55
Neurotransmitterhypothesen der Schizophrenie ............................................................................. 55
Dopaminhypothese ....................................................................................................................... 55

2

, revidierte Dopaminhypothese ...................................................................................................... 55
Glutamat ........................................................................................................................................ 56
Serotonin ....................................................................................................................................... 56
Befund von Metaanalysen und PET-Studien ................................................................................. 56
Antipsychotika-Einteilung nach chemischer Struktur ....................................................................... 56
Konventionelle vs. Atypische Antipsychotika (KAP/AAP) .............................................................. 57
Rezeptorbindungen: D2-artige Rezeptoren .................................................................................. 58
Unerwünschte Wirkungen der Antipsychotika ................................................................................. 58
Zeitlicher Verlauf der Therapie...................................................................................................... 61
Affektive Störungen ................................................................................................................... 62
Endogene Depression........................................................................................................................ 62
Hypothesen zur Neurobiologie der Depression ................................................................................ 62
Neurotransmitterhypothesen ....................................................................................................... 63
Neuroendokrinologische Hypothesen........................................................................................... 64
Antidepressiva ................................................................................................................................... 64
Allgemeine Therapiekonzepte........................................................................................................... 66
Trizyklische Antidepressiva ............................................................................................................... 68
Biochemische Wirkungen .............................................................................................................. 68
Anticholinerge Nebenwirkungen .................................................................................................. 68
Antihistaminerge Nebenwirkungen .............................................................................................. 68
Selektive Serotonin-Wiederaufnahmehemmer (SSRI) ...................................................................... 69
Allgemeine Nebenwirkungen ........................................................................................................ 69
Monoaminoxidasehemmer (MAOH) ................................................................................................. 70
Neuartige Antidepressiva .................................................................................................................. 70
Agomelatin .................................................................................................................................... 70
Johanniskraut ................................................................................................................................ 71
Ketamin ......................................................................................................................................... 71
Vergleich von Antidepressiva ............................................................................................................ 71
Phasenprophylaxe mit Lithium.......................................................................................................... 71
Wirkmechanismen......................................................................................................................... 72
Kontraindikation ............................................................................................................................ 72
Lithiumintoxikation ....................................................................................................................... 72
Antikonvulsiva in der Phasenprophylaxe .......................................................................................... 73
Angst- und Zwangsstörungen ...................................................................................................... 73
Zwang ................................................................................................................................................ 73
Prävalenz /Verlauf ......................................................................................................................... 74

3

, Evidenz für genetische Faktoren bei OCD ..................................................................................... 74
Risikogene/ –allele für die Zwangsstörung ................................................................................... 74
Genetische Tiermodelle der Zwangsstörung................................................................................. 75
Neurobiologie ................................................................................................................................ 75
Pharmakotherapie ......................................................................................................................... 75
experimentelle Therapieansätze ................................................................................................... 76
Angst .................................................................................................................................................. 76
Lebenszeitprävalenz ...................................................................................................................... 77
lerntheoretische Erklärung ............................................................................................................ 77
Modell der 2-Faktoren-Theorie ..................................................................................................... 78
Komorbidität ................................................................................................................................. 78
Bereichsspezifische Ängste und ihr evolutionärer Hintergrund ................................................... 78
Neurobiologie ................................................................................................................................ 79
Pharmakologische Therapie der Angststörungen ......................................................................... 80
Stufenschema der Pharmakotherapie........................................................................................... 80
Wahl der Psychopharmaka bei Angststörungen ........................................................................... 80
Benzodiazepine ............................................................................................................................. 81
GABA-Rezeptoren .......................................................................................................................... 81
GABAA-Rezeptor und Liganden...................................................................................................... 82
Andere Anxiolytika ........................................................................................................................ 82
Sucht ......................................................................................................................................... 83
Definitionen ....................................................................................................................................... 83
Riskanter Konsum .......................................................................................................................... 83
Missbrauch / schädlicher Gebrauch .............................................................................................. 83
Abhängigkeit .................................................................................................................................. 83
Wirkung und Wirkorte einiger Suchtmittel ....................................................................................... 84
Neurobiologie .................................................................................................................................... 84
Suchtentwicklung .............................................................................................................................. 85
Toleranz ......................................................................................................................................... 85
Akute und repetitive Wirkung ....................................................................................................... 86
Entzugssymptome ............................................................................................................................. 86
Alkohol............................................................................................................................................... 87
Alkoholabhängigkeit: Therapieprinzipien...................................................................................... 87
Akute Intoxikation mit Alkohol ...................................................................................................... 87
Alkoholentzugssyndrom ................................................................................................................ 88
Therapie des Alkoholentzugssyndroms......................................................................................... 88

4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller 4542959. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $5.02. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

53022 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$5.02  2x  sold
  • (0)
Add to cart
Added